ERBB3 and neoplasm: Using primary CAFs derived from tumour tissue of luminal breast cancer patients, we demonstrate how heterogeneous expression of NRG1 in CAFs determines response of cancer cells to therapies blocking the HER3 signaling pathway [35, 36].